

Special Issue

Thymoma and Thymic Carcinoma: Therapy and Outcomes

Message from the Guest Editors

In view of your expertise, we are pleased to invite you to submit an article for the Special Issue *“Thymoma and Thymic Carcinoma: Therapy and Outcomes”* for the journal *Cancers*. This Special Issue aims to review and analyse current knowledge and clinical practice applied to thymic malignancies, and their short- and long-term outcomes. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: surgery for thymic malignancies, radiotherapy for thymic malignancies, oncological treatments for thymic malignancies, thymic malignancies and myasthenia gravis, follow-up in thymic malignancies, and outcomes in thymic malignancies. We look forward to receiving your contribution.

Guest Editors

Prof. Dr. Enrico Ruffini

Prof. Dr. Pier Luigi Filosso

Dr. Paraskevas Lyberis

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/99535

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)